Deciphering KRAS and NRAS mutated clone dynamics in MLL-AF4 paediatric leukaemia by ultra deep sequencing analysis.

Blinatumomab-induced lineage switch of B-ALL with t(4:11)(q21;q23) KMT2A/AFF1 into an aggressive AML: pre- and post-switch phenotypic, cytogenetic and molecular analysis. Blood Cancer J (2017) 0.75

Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci U S A (2005) 167.46

Exploration, normalization, and summaries of high density oligonucleotide array probe level data. Biostatistics (2003) 100.88

Sequencing technologies - the next generation. Nat Rev Genet (2009) 40.57

The Connectivity Map: using gene-expression signatures to connect small molecules, genes, and disease. Science (2006) 25.99

Adjusting batch effects in microarray expression data using empirical Bayes methods. Biostatistics (2006) 22.61

Targeting RAS signalling pathways in cancer therapy. Nat Rev Cancer (2003) 15.17

Cytoscape Web: an interactive web-based network browser. Bioinformatics (2010) 10.03

The genetic basis of early T-cell precursor acute lymphoblastic leukaemia. Nature (2012) 9.89

Performance comparison of benchtop high-throughput sequencing platforms. Nat Biotechnol (2012) 8.99

Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer. Nature (2012) 8.77

MLL translocations, histone modifications and leukaemia stem-cell development. Nat Rev Cancer (2007) 8.17

The roles of FLT3 in hematopoiesis and leukemia. Blood (2002) 6.14

H3K79 methylation profiles define murine and human MLL-AF4 leukemias. Cancer Cell (2008) 5.23

Molecular mechanisms of leukemogenesis mediated by MLL fusion proteins. Oncogene (2001) 4.70

Clinical utility of microarray-based gene expression profiling in the diagnosis and subclassification of leukemia: report from the International Microarray Innovations in Leukemia Study Group. J Clin Oncol (2010) 4.09

Inhibition of FLT3 in MLL. Validation of a therapeutic target identified by gene expression based classification. Cancer Cell (2003) 3.75

Unraveling the complexity of tyrosine kinase inhibitor-resistant populations by ultra-deep sequencing of the BCR-ABL kinase domain. Blood (2013) 2.53

Clinical impact of small TP53 mutated subclones in chronic lymphocytic leukemia. Blood (2014) 2.53

The landscape of somatic mutations in infant MLL-rearranged acute lymphoblastic leukemias. Nat Genet (2015) 2.34

Accurate ranking of differentially expressed genes by a distribution-free shrinkage approach. Stat Appl Genet Mol Biol (2007) 2.31

Clinical experience of MEK inhibitors in cancer therapy. Biochim Biophys Acta (2006) 2.28

Small molecule enoxacin is a cancer-specific growth inhibitor that acts by enhancing TAR RNA-binding protein 2-mediated microRNA processing. Proc Natl Acad Sci U S A (2011) 2.21

Gene expression profiling-based dissection of MLL translocated and MLL germline acute lymphoblastic leukemia in infants. Blood (2009) 2.19

Reliable detection of subclonal single-nucleotide variants in tumour cell populations. Nat Commun (2012) 2.06

Mutation of genes affecting the RAS pathway is common in childhood acute lymphoblastic leukemia. Cancer Res (2008) 1.77

Overcoming bias and systematic errors in next generation sequencing data. Genome Med (2010) 1.75

Patient-derived induced pluripotent stem cells recapitulate hematopoietic abnormalities of juvenile myelomonocytic leukemia. Blood (2013) 1.73

Clinical heterogeneity in childhood acute lymphoblastic leukemia with 11q23 rearrangements. Leukemia (2003) 1.64

Downstream of mutant KRAS, the transcription regulator YAP is essential for neoplastic progression to pancreatic ductal adenocarcinoma. Sci Signal (2014) 1.61

The AF4.MLL fusion protein is capable of inducing ALL in mice without requirement of MLL.AF4. Blood (2010) 1.60

The Interlaboratory RObustness of Next-generation sequencing (IRON) study: a deep sequencing investigation of TET2, CBL and KRAS mutations by an international consortium involving 10 laboratories. Leukemia (2011) 1.55

Mechanisms of leukemogenesis by MLL fusion proteins. Br J Haematol (2010) 1.49

K-Ras mutations and N-Ras mutations in childhood acute leukemias with or without mixed-lineage leukemia gene rearrangements. Cancer (2006) 1.39

A murine Mll-AF4 knock-in model results in lymphoid and myeloid deregulation and hematologic malignancy. Blood (2006) 1.35

MEK1 and MEK2 inhibitors and cancer therapy: the long and winding road. Nat Rev Cancer (2015) 1.27

Dimerization of MLL fusion proteins and FLT3 activation synergize to induce multiple-lineage leukemogenesis. J Clin Invest (2005) 1.26

Targeting FLT3 in primary MLL-gene-rearranged infant acute lymphoblastic leukemia. Blood (2005) 1.20

Improved outcome with hematopoietic stem cell transplantation in a poor prognostic subgroup of infants with mixed-lineage-leukemia (MLL)-rearranged acute lymphoblastic leukemia: results from the Interfant-99 Study. Blood (2010) 1.18

Robustness of amplicon deep sequencing underlines its utility in clinical applications. J Mol Diagn (2013) 1.13

Frequencies and prognostic impact of RAS mutations in MLL-rearranged acute lymphoblastic leukemia in infants. Haematologica (2013) 1.11

A conditional model of MLL-AF4 B-cell tumourigenesis using invertor technology. Oncogene (2006) 1.09

MEK inhibitor PD0325901 significantly reduces the growth of papillary thyroid carcinoma cells in vitro and in vivo. Mol Cancer Ther (2010) 1.08

Implementation of array based whole-genome high-resolution technologies confirms the absence of secondary copy-number alterations in MLL-AF4-positive infant ALL patients. Leukemia (2010) 1.05

Opposing activities of the Ras and Hippo pathways converge on regulation of YAP protein turnover. EMBO J (2014) 1.04

DNA copy-number abnormalities do not occur in infant ALL with t(4;11)/MLL-AF4. Leukemia (2009) 1.03

The transcriptomic landscape and directed chemical interrogation of MLL-rearranged acute myeloid leukemias. Nat Genet (2015) 1.03

Activated K-Ras protein accelerates human MLL/AF4-induced leukemo-lymphomogenicity in a transgenic mouse model. Leukemia (2011) 0.97

RAS diseases in children. Haematologica (2014) 0.95

Two independent gene signatures in pediatric t(4;11) acute lymphoblastic leukemia patients. Eur J Haematol (2009) 0.92

Clonal variegation and dynamic competition of leukemia-initiating cells in infant acute lymphoblastic leukemia with MLL rearrangement. Leukemia (2014) 0.90

Revisiting the biology of infant t(4;11)/MLL-AF4+ B-cell acute lymphoblastic leukemia. Blood (2015) 0.88

The silent mutational landscape of infant MLL-AF4 pro-B acute lymphoblastic leukemia. Genes Chromosomes Cancer (2013) 0.87

Low PKCα expression within the MRD-HR stratum defines a new subgroup of childhood T-ALL with very poor outcome. Oncotarget (2014) 0.86

Ouabain sensitivity is linked to ras -transformation in human HOS cells. Biochem Biophys Res Commun (1986) 0.86

Secondary mutations in t(4;11) leukemia patients. Leukemia (2012) 0.84

Activated KRAS Cooperates with MLL-AF4 to Promote Extramedullary Engraftment and Migration of Cord Blood CD34+ HSPC But Is Insufficient to Initiate Leukemia. Cancer Res (2016) 0.81

Subclonality and prenatal origin of RAS mutations in KMT2A (MLL)-rearranged infant acute lymphoblastic leukaemia. Br J Haematol (2015) 0.79

Acetoxycycloheximide and cycloheximide convert transformed morphology of ras-transformed cells to normal morphology. J Antibiot (Tokyo) (1989) 0.76

Induction of flat morphology in K-ras-transformed fibroblasts by lycorine, an alkaloid isolated from the tropical plant Eucharis grandiflora. Drugs Exp Clin Res (1997) 0.76

The IRX1/HOXA connection: insights into a novel t(4;11)- specific cancer mechanism. Oncotarget (2016) 0.76

Metformin inhibits cell cycle progression of B-cell chronic lymphocytic leukemia cells. Oncotarget (2015) 0.78

Functional Activation of Osteoclast Commitment in Chronic Lymphocytic Leukaemia: a Possible Role for RANK/RANKL Pathway. Sci Rep (2017) 0.75